Wenwen Zhang

发表

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

S. Vermeire, G. D'Haens, F. Baert, 2021, Journal of Crohn's & colitis.

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

C. Almansa, M. Bari, M. Rosario, 2021, Clinical pharmacology : advances and applications.

950 THE VISIBLE 2 PHASE 3 STUDY OF EFFICACY AND SAFETY OF VEDOLIZUMAB SC FOR MODERATE-TO-SEVERE CROHN'S DISEASE

S. Vermeire, G. D'Haens, F. Baert, 2020 .

Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials

E. Dellon, I. Hirano, D. Katzka, 2023, Alimentary pharmacology & therapeutics.

S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE

W. Sandborn, S. Danese, S. Adsul, 2020 .

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D2/D3 receptor antagonist, in patients with gastroparesis

M. Camilleri, B. Kuo, G. Dukes, 2021, Alimentary pharmacology & therapeutics.

Creation of an apoptin-derived peptide that interacts with SH3 domains and inhibits glioma cell migration and invasion

Weiwei Song, Zhongqi Cui, Di Wang, 2016, Tumor Biology.

Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis

E. Dellon, G. Falk, I. Hirano, 2023, Journal of pediatric gastroenterology and nutrition.

Su1173: EFFECT OF PRIOR ESOPHAGEAL DILATION ON HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

E. Dellon, G. Falk, I. Hirano, 2022, Gastroenterology.